Communiqués Glenmark Pharmaceuticals Limited

Actions

GLENMARK

INE935A01035

Temps Différé NSE India S.E. Autres places de cotation 11:39:08 07/06/2024			Varia. 5j.	Varia. 1 janv.
1 192 ^INR	-1,51 %		+2,77 %	+39,64 %

30/05	Transcript : Glenmark Pharmaceuticals Limited - Analyst/Investor Day
29/05	Assertio Therapeutics nomme Brendan O'Grady au poste de directeur general	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Glenmark Pharmaceuticals : Investor Day 2024	04/06	PU
Glenmark Pharmaceuticals : Investors Day 2024	30/05	PU
Glenmark Pharmaceuticals : Q4FY 2023-24	29/05	PU
Glenmark Pharmaceuticals : Q4 FY 2023-24	27/05	PU
Glenmark Pharmaceuticals : Pharma Reports Q4 FY2023-24 Financial results	24/05	PU
Glenmark Pharmaceuticals receives ANDA approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%\|0.5%	20/05	AQ
Glenmark Pharmaceuticals : receives ANDA approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%\|0.5%	17/05	PU
Glenmark Pharmaceuticals Ltd. reports Consolidated Revenue of Rs. 29,096 Mn for Q3 FY 2023 24	15/02	AQ
Glenmark and Ichnos take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance 'Ichnos Glenmark Innovation'	31/01	AQ
Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 for Multiple Geographies around the World	26/01	AQ
Glenmark Pharmaceuticals : is the first to launch Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India	03/01	PU
Glenmark Pharma is first to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-morbidities	19/10/23	AQ
Fitch Affirms Glenmark Pharmaceuticals at 'BB'; Outlook Stable	04/10/23	AQ
COSMO AND GLENMARK ANNOUNCE THE SIGNING OF DISTRIBUTION AND LICENSE AGREEMENTS FOR WINLEVI IN EUROPE AND SOUTH AFRICA	28/09/23	AQ
Glenmark Pharmaceuticals : FY 2022-23	04/09/23	PU
Glenmark Pharmaceuticals : Q1FY 2023-24	21/08/23	PU
Glenmark Pharmaceuticals receives sANDA approval for Tacrolimus Ointment, 0.03%	18/08/23	AQ
Glenmark Pharma reports revenue growth of 22.5%, EBITDA growth of 46.2% YoY for Q1 FY 2023 24	14/08/23	AQ
Glenmark Pharmaceuticals receives ANDA approval for Saxagliptin Tablets, 2.5 mg and 5 mg	01/08/23	AQ
Fitch Affirms Glenmark Pharmaceuticals at 'BB'; Outlook Stable	20/06/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Glenmark Pharmaceuticals Limited

Actions

GLENMARK

INE935A01035

Communiqués

Filtres